The content is available as a PDF (357.9 KB).
letter . 2020 Dec 22:jjaa259. doi: 10.1093/ecco-jcc/jjaa259
Recurrent COVID-19 in a patient with ulcerative colitis on vedolizumab therapy
Femke Crouwel
1,✉, Petra Waaijenberg-Warmenhoven
2, Hans J C Buiter
3, Nanne K de Boer
1
Femke Crouwel
1
Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Find articles by Femke Crouwel
Petra Waaijenberg-Warmenhoven
2
Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Find articles by Petra Waaijenberg-Warmenhoven
Hans J C Buiter
3
Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Find articles by Hans J C Buiter
Nanne K de Boer
1
Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Find articles by Nanne K de Boer
1
Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
2
Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
3
Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
✉
Corresponding Author: Femke Crouwel, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands, Telephone number: +31204440799, Fax number: +31204440554, Email: f.crouwel@amsterdamumc.nl.nl
Received 2020 Dec 5.
Keywords: ulcerative colitis, vedolizumab, COVID-19
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC7799231 PMID: 33350449